A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

NCT03945799 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
28
Enrollment
OTHER
Sponsor class

Stopped The study has gotten preliminary results and stopped advanced.

Conditions

Interventions

Sponsor

Zhejiang University

Collaborators